Source: http://www.google.es/patents/US9023401
Timestamp: 2018-01-22 08:49:57
Document Index: 197638006

Matched Legal Cases: ['Application No. 60', 'application No. 200910132824', 'application No. 200810125922', 'Application No. 155', 'Application No. 2001', 'Application No. 2006', 'Application No. 10177508', 'Application No. 10180945', 'art 1', 'Application No. 01', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 05019453', 'Application No. 01992565', 'Application No. 10177508', 'Application No. 10179086', 'Application No. 10179087', 'Application No. 10180984', 'Application No. 10181032', 'application No. 01992565', 'application No. 10', 'application No. 2013']

Patente US9023401 - Controlled release hydrocodone formulations - Google Patentes
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material....http://www.google.es/patents/US9023401?utm_source=gb-gplus-sharePatente US9023401 - Controlled release hydrocodone formulations
Número de publicación US9023401 B1
Número de solicitud US 14/581,175
También publicado como CA2427815A1, CA2427815C, CN1479614A, CN100518827C, CN101317825A, CN101653411A, CN103690540A, EP1337244A1, EP1337244A4, EP2263658A1, EP2283829A1, EP2295042A1, EP2932964A1, US6733783, US7514100, US8142811, US8231898, US8361499, US8551520, US8647667, US8715721, US8951555, US9056052, US9060940, US9198863, US9205055, US9205056, US9289391, US9504681, US9517236, US9526724, US9572804, US9572805, US9669023, US9682077, US20020192277, US20040047907, US20090202629, US20110038927, US20120263788, US20130158061, US20130295177, US20130302418, US20140199394, US20150037409, US20150110870, US20150148367, US20150238418, US20150258089, US20150258090, US20150265537, US20160151288, US20160151292, US20160151361, US20160158223, US20160158224, US20170087151, US20170087152, US20170151229, WO2002036099A1
Número de publicación 14581175, 581175, US 9023401 B1, US 9023401B1, US-B1-9023401, US9023401 B1, US9023401B1
Citas de patentes (470), Otras citas (183), Citada por (18), Clasificaciones (29)
US 9023401 B1
1. A solid oral controlled-release dosage form of hydrocodone, the dosage form comprising a plurality of multiparticulates comprising an amount of a hydrocodone bitartrate salt equivalent to from about 5 mg to about 60 mg of hydrocodone and a controlled release material,
the plurality of multiparticulates compressed into a tablet,
wherein said hydrocodone bitartrate salt is the only active agent in the dosage form.
5. A solid oral controlled-release dosage form of hydrocodone, the dosage form comprising a plurality of multiparticulates comprising an amount of a hydrocodone bitartrate salt equivalent to from about 5 mg to about 60 mg of hydrocodone and a controlled release material, the multiparticulates individually coated with a controlled-release coating and compressed into a tablet,
the controlled release material included in an effective amount such that the dosage form provides a W50 of hydrocodone of between 4 and 22 hours and a plasma concentration of hydrocodone within a therapeutic range but below toxic concentrations over a period of time of about 12 hours or longer after administration to a human patient or a population of patients,
11. A solid oral controlled-release dosage form of hydrocodone, the dosage form comprising a plurality of pharmaceutically acceptable matrices comprising an amount of a hydrocodone bitartrate salt equivalent to from about 5 mg to about 60 mg of hydrocodone and a controlled release material, the pharmaceutically acceptable matrices individually coated with a controlled-release coating and compressed into a tablet,
the dosage form providing a Tmax of hydrocodone of from about 4 to about 10 hours and a plasma concentration of hydrocodone within a therapeutic range but below toxic concentrations over a period of time of about 12 hours or longer after administration to a human patient or a population of patients,
15. The dosage form of claim 12, wherein the pharmaceutically acceptable matrices further comprise hydroxypropylmethylcellulose.
16. The dosage form of claim 11, wherein the controlled release material comprises a material selected from the group consisting of gums, cellulose ethers, acrylic resins, waxes, shellac and oils.
17. A solid oral controlled-release dosage form of hydrocodone, the dosage form comprising a plurality of pharmaceutically acceptable matrices comprising an amount of a hydrocodone bitartrate salt equivalent to from about 5 mg to about 60 mg of hydrocodone and a controlled release material,
the pharmaceutically acceptable matrices compressed into a tablet,
the controlled release material included in an effective amount such that the dosage form provides a Tmax of hydrocodone of from about 4 to about 10 hours and a plasma concentration of hydrocodone within a therapeutic range but below toxic concentrations over a period of time of about 12 hours or longer after administration to a human patient or a population of patients,
18. The dosage form of claim 17, wherein the controlled release material comprises a material selected from the group consisting of gums, cellulose ethers, acrylic resins, waxes, shellac and oils.
19. The dosage form of claim 18, wherein the material comprises ethylcellulose.
20. The dosage form of claim 19, wherein the pharmaceutically acceptable matrices further comprise hydroxypropylmethylcellulose.
21. The dosage form of claim 15, wherein the controlled release material comprises ethylcellulose.
22. The dosage form of claim 17, wherein the controlled release material is included in an effective amount such that the dosage form provides an in-vitro release of hydrocodone when measured by the USP Basket method at 100 rpm in 700 ml aqueous buffer at a pH of 1.2 at 37° C. of from 10% to about 45% by weight hydrocodone released at 1 hour.
23. The dosage form of claim 17, wherein the dosage form provides the plasma concentration of hydrocodone within the therapeutic range but below toxic concentrations over a period of time of about 12 hours after administration to the human patient or the population of patients.
24. The dosage form of claim 23, wherein said administration is first administration.
25. The dosage form of claim 17, wherein said administration is first administration.
26. The dosage form of claim 4, wherein the controlled release material comprises ethylcellulose.
27. The dosage form of claim 26, wherein the multiparticulates further comprise hydroxypropylmethylcellulose.
28. The dosage form of claim 17, which provides a W50 of hydrocodone of between 4 and 22 hours.
29. The dosage form of claim 5, which provides a Tmax of hydrocodone of from about 4 to about 10 hours.
30. The dosage form of claim 16, wherein the acrylic resin comprises an ammonio methacrylate copolymer.
This application is a continuation of U.S. patent application Ser. No. 14/520,032, filed on Oct. 21, 2014, which is a continuation of U.S. patent application Ser. No. 14/210,565, filed on Mar. 14, 2014, which is a continuation of U.S. patent application Ser. No. 13/901,069, filed on May 23, 2013, now U.S. Pat. No. 8,715,721, which is a continuation of U.S. patent application Ser. No. 13/721,293, filed on Dec. 20, 2012, now U.S. Pat. No. 8,551,520, which is a continuation of U.S. patent application Ser. No. 13/535,996, filed on Jun. 28, 2012, now U.S. Pat. No. 8,361,499, which is a continuation of U.S. patent application Ser. No. 12/914,054, filed on Oct. 28, 2010, now U.S. Pat. No. 8,231,898, which is a divisional of U.S. patent application Ser. No. 12/378,586, filed on Feb. 17, 2009, now U.S. Pat. No. 8,142,811, which is a continuation of U.S. patent application Ser. No. 10/660,349, filed on Sep. 11, 2003, now U.S. Pat. No. 7,514,100, which is a continuation of U.S. patent application Ser. No. 10/016,651, filed Oct. 30, 2001, now U.S. Pat. No. 6,733,783, which claims the benefit of U.S. Provisional Application No. 60/244,424, filed Oct. 30, 2000, all hereby incorporated by reference.
Other additional drugs include nontoxic NMDA receptor antagonists such dextrorphan, dextromethorphan, 3-(1-naphthalennyl)-5-(phosphonomethyl)-L-phenylalanine, 3-(1-naphthalenyl)-5-(phosphonomethyl)-DL-phenylalanine, 1-(3,5-dimethylphenyl)naphthalene, and 2-(3,5-dimethylphenyl)naphthalene, 2SR,4RS-4-(((1H-Tetrazol-5-yl)methyl)oxy) piperidine-2-carboxylic acid; 2SR,4RS-4-((((1H-Tetrazol-5-yl)methyl)oxy) methyl)piperidine-2-carboxylic acid; E and Z 2SR-4-(O-(1H-Tetrazol-5-yl)methyl)ketoximino) piperidine-2-carboxylic acid; 2SR,4RS-4-((1H-Tetrazol-5-yl)thio)piperidine-2-carboxylic acid; 2SR,4RS-4-(((1H-Tetrazol-5-yl)thio)piperidine-2-carboxylic acid; 2SR,4RS-4-(5-mercapto-1H-Tetrazol-1-yl)piperidine-2-carboxylic acid; 2SR,4RS-4-(5-mercapto-2H-Tetrazol-2-yl)piperidine-2-carboxylic acid; 2SR,4RS-4-(5-mercapto-1H-Tetrazol-1-yl)piperidine-2-carboxylic acid; 2SR,4RS-4-(5-mercapto-2H-Tetrazol-2-yl)piperidine-2-carboxylic acid; 2SR,4RS-4-(((1H-Tetrazol-5-yl)thio)methyl)piperidine-2-carboxylic acid; 2SR,4RS-4-((5-mercapto-1H-Tetrazol-1-yl)methyl) piperidine-2-carboxylic acid; or 2SR,4RS-4-((5-mercapto-2H-Tetrazol-2-yl)methyl)piperidine-2-carboxylic acid, their mixtures and pharmaceutically acceptable salts thereof.
(hour) Dissolved
hour SGE/SIF
WO1997033566A3 28 Feb 1997 6 Nov 1997 Alza Corp Composition and dosage form comprising opioid antagonist
WO2004093819A3 21 Abr 2004 3 Mar 2005 Euro Celtique Sa Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
11 An English translation of the Decision on Reexamination issued in connection with Chinese patent application No. 200910132824.3 on Nov. 5, 2014.
12 An English translation of the Notice on Reexamination issued in connection with Chinese patent application No. 200810125922.X on Dec. 3, 2014.
13 An English translation of the Office Action issued in connection with Israeli Patent Application No. 155,637 on Nov. 16, 2014.
14 Approval Package for NDA 20-616/5-001 (Kadian®), 1997.
15 Benziger, et al., "A Pharmacokinetic/Pharmacodynamic Study of Controlled-Release Oxycodone", 1997.
16 Brendenberg "New Concepts in Administration of Drugs in Tablet Form: Formulation and Evaluation of a Sublingual Tablet for Rapid Absorption and Presentation of an Individualized Dose Administration System Acta Universitiatis Upsaliensis." Comprehensive Summaries of Uppsa/a Dissertations from the Faculty of Pharmacy287 83 pp. Uppsala ISBN 91-554-560-6 (2003).
17 Broomhead, et al., "Kadian™/Kapanol™-A Once Daily Mophine Formulation," European Journal of Cancer; Part A General Topics 1995:31 (S5) Suppl: S182 Abs 873, European Conference on Clinical Onclology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995.
18 Castensen et al., "USP Dissolution IV:Comparison of Methods," J. Pham. Sci 1978, 67(9), pp. 1303-1307.
19 Certain Patients Diary Cards, Drug Disposition Records, Case Reports Forms and listing which apparently correlates patient randomization number with the treatment of dosing regimen assigned to each patient, 2003.
20 Cherry DA, et al., "A comparison of Kapanol™ (a new sustained release morphine formulation), MST Continus™ and morphine solution in cancer patients: Morphine metabolite profiles and renal function," (Abstract 999) International Association for the Study of Pain, 7th World Congress on Pain, Paris Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
21 Cherry DA, et al., "Once a Day (i.e. 24 Hourly) Kapanol™, A New Sustained Release Morphine Formulation, in the Treatment of Cancer Pain: Morphine Metabolite Profiles," European Journal of Cancer; Part A General Topics 1995; 31 (S5) Suppl:S184 Abs 884, European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995.
22 Claims pending in U.S. Appl. No. 12/982,386 on Jan. 5, 2015.
23 Claims pending in U.S. Appl. No. 12/982,386 on May 7, 2014.
24 Claims Pending in U.S. Appl. No. 12/982,386 on Oct. 20, 2014.
25 Claims pending in U.S. Appl. No. 13/833,263 on Jan. 5, 2015.
26 Claims pending in U.S. Appl. No. 13/833,263 on May 7, 2014.
27 Claims Pending in U.S. Appl. No. 13/833,263 on Oct. 20, 2014.
28 Claims pending in U.S. Appl. No. 14/094,968 on Jan. 5, 2015.
29 Claims pending in U.S. Appl. No. 14/094,968 on May 7, 2014.
30 Claims Pending in U.S. Appl. No. 14/094,968 on Oct. 20, 2014.
31 Claims pending in U.S. Appl. No. 14/483,395 on Jan. 13, 2015.
32 Claims Pending in U.S. Appl. No. 14/483,395 on Oct. 20, 2014.
33 Claims pending in U.S. Appl. No. 14/612,483 on Feb. 11, 2015.
34 Clin. Neuropharmacol (1999) Jan.-Feb.; 22 (1):33-9).
35 Clin. Pharmacokinet (1998) Sep.; 35(3):173-90.
36 Conte. et al., Drug Del.. Ind. Pharm. (1989) 15:2583-2596.
37 D.L. Munday, et al., "Changes in Drug Release Rate 2. Effect of Temperature and Relative Humidity on Polymeric Film Coatings," 5th Cong. Int. Tech. Pharm., 1989, vol. 2, pp. 55-60.
38 Database Medline [Online] US National Library of Medicine (NLM), Bethesda, MD, US; Aug. 1994, Yasuhara H: "Ethnic factors in evaluation of drug efficacy and safety," XP002350633 Database accession No. NLM7927070.
39 Document CA/PL 17/07; "Misuse of Divisional Applications," by the EPO President, addressed to the EPO Committee of Patent Law. Presented at the EPO Administrative Council, dated Oct. 5, 2007.
40 Document CA/PL 3/08, presented by epi and other Professional Representatives, addressed to the EPO Committee of Patent Law. Presented at the EPO Administrative Council, dated Feb. 14, 2008.
41 Drugs (1999) Jan.; 57(1 ):93-9.
42 E.Beubler, "Medikamentose Schmerztherapie: Kriterien, Moglichkeiten, Risken," Therapiewoche Osterreich, 7,2 (1992), pp. 1-15, English translation.
43 Emami, J. et al, "In vitro- In vivo Correlation: From Theory to Applications", J. Pharm Pharmaceut Sci, (www.cspsCanada.org) 9 (2), 169-189, 2006.
44 Encarta World English Dictionary [North American Edition] 2006 Microsoft Incorporation "Matrix", p. 1, definition 2, http://encarta.msn.com/encnet/features/dictionary/DictionaryResults.aspx?-refid=1861678516 retrieved on Apr. 30, 2006.
45 Encyclopedia of Controlled Drug Delivery, vol. 1, "In vitro-in vivo correlation," pp. 425-435 (1999).
46 Encyclopedia of Controlled Drug Delivery, vol. 2, "Oral drug delivery, small intestine & colon," pp. 698-728 (1999).
47 English Abstract of JP-08157392-A, Jun. 18, 1996.
48 English translation of Office Action issued by Japanese Patent Office in connection with corresponding Japanese Patent Application No. 2001-534353 on May 25, 2010.
49 English Translation of the Office Action issued on Mar. 22, 2011 in connection with Japanese Patent Application No. 2006-3165067.
50 EPI Journal Feb. 2007, pp. 59-60; David Harrison; "Divisional Application a continuing problem" (2007).
51 Eur. J. Pharm. Sci. (1999) Jul.; 8(3):157-9.
52 European Search Report issued in connection with European Application No. 10177508.8-2123 on Sep. 11, 2010.
53 European Search Report issued on Nov. 9, 2010 in connection with European Application No. 10180945.7-2123.
54 FDA Response to a Citizen Petition, Docket No. FDA-2013-P-0703, Oct. 25, 2013.
55 Flanders, P., et al., "The Control of Drug Release From Conventional Melt Granulation Matrices," Drug Development and Industrial Pharmacy, vol. 13, No. 6, pp. 1001-1022 (1987).
56 Frohof-Hulsmann et al., "Aqueous Ethyl Cellulose Dispersion Containing Plasticizers of Different Water Solubility and Hydroxypropyl Methyl-Cellulose as Coating Material for Diffusion Pellets II: Properties of Sprayed Films", European Journ. of Pharma and Biopharma., vol. 48, pp. 67-75, 1999.
57 Geoffrey K. Gourlay, et al.,"The Reproducibility of Bioavailability of Oral Morphine from Solution Under Fed and Fasted Conditions," Journal of Pain and Symtoms Management, vol. 6., No. 7, Oct. 1991, pp. 431-436.
58 Giunchedi et al., J. Pharm. (1991) 77:177-181.
59 Goodman and Gilman's, The Pharmacological Basis of Therapeutics, pp. 7-8 (1990).
60 Gourlay et al., "Proceedings of the 7th World Congress on Pain; A comparison of Kapanol (a New Sustained-Release Morphine Formulation), MST Continus, and Morphine Solution in Cancer Patients," Pharmacolinetic Aspects of Morphine and Morphine Metabolites Progress in Pain Research and Management vol. 2 pp. 631-643, 1993.
61 Gourlay GK, et al., "A comparison of Kapanol™ (a new sustained release morphine formulation), MST Contius® and morphine solution in cancer patients: pharmacokinetics aspects," (Abstract 998) International Association for the Study of Pain, 7th World Congress on Pain Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
62 Gourlay, et al., "Influence of a High-Fat Metal on the Absorption of Morphine From Oral Solutions," Clin. Pharmacol. Ther., vol. 46, Oct. 1989, pp. 463-468.
63 Gourlay, et al., "Once a Day (i.e. 24 Hourly) Kapanol™, A New Sustained Release Morphine Formulation, in the Treatment of Cancer Pain: Pharmacokinetic Aspects," European Journal of Cancer; Part A General Topics 1995:31 (S5) Suppl: S187 Abs 897, European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995.
64 Guidance for Industry, "Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/ In vivo Correlation" (FDA, 1997).
65 Guidance for Industry, Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/ In Vivo Correlations; US Dept. of Health and Human Services Food and Drug Administration; Center for Drug Evaluation and Research (CDER), Sep. 1997, pp. 1-24.
66 Gustafsson et al., "Characterisation of Particle Properties and Compaction Behaviour of Hydroxypropyl Methylcellulose with Different Degrees of Methoxy/Hydroxypropyl Substitution", EP Journ of Pharmaceutical Sci. 9, pp. 171-184, 1999.
67 H.F. Stowey et al., "Effect of Premedication with Controlled-Release Oral Morphine on Postoperative Pain," Anesthesia, 1985, vol. 40, pp. 438-440.
68 Hansch C et al.,"Comprehensive Medicinal Chemistry, vol. 5 Biopharmaceutics," Rational Design, Mechanistic Study and Therapeutic Application of Chemical Compounds, Oxford, Pergamon Press, GB, vol. 5, 1990, pp. 251-278, XP008054499.
69 Hyppola et al.,"Evaluation of Physical Properties of Plasticized Ethyl Cellulose Films Cast From Ethanol Solution Part 1", International Journ. of Pharma., vol. 133, pp. 161-170, 1996.
70 International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/025914 dated Aug. 28, 2012.
71 International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/035767 dated Nov. 13, 2012.
72 International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/035768 dated Nov. 13, 2012.
73 International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/035770 dated Nov. 13, 2012.
74 International Search Report and Written Opinion for PCT/US2007/020041, dated Feb. 25, 2008.
75 Investigator agreements between the study organizers and certain of the principal investigators, 2003.
76 J. Control Release Aug. 5, 1999; 60(2-3):391-7.
77 J. Lapin et al., "Cancer Pain Management with a Controlled Release Oral Morphine Preparation," Pain and Symptom Manag., vol. 4 (3), pp. 146-151,1989.
78 J. Lapin et al., "Guidelines for Use of Controlled Release Oral Morphine in Cancer Pain Management," Cancer Nursing, vol. 12 (4), pp. 202-208, (1989).
79 J. Pharm. Pharmacol (1996) Dec.; 48(12):1276-84.
80 J. Pharm. Sci. (1993) Feb.; 82(2):113-26.
81 Johnson, Sarah J., "Opioid Safety in Patients With Renal or Hepatic Dysfunction" Pain Treatment Topics pp. 1-9 (Release date Jun. 2007; updated Nov. 30, 2007).
82 Kadian® Prescribing Information 2006.
83 Kaiko et al., "A Single-Dose Study of the Effect of Food Ingestion and Timing of Dose Administration on the Pharmacokinetic Profile of 30-mg Sustained-Release Morphine Sulfate Tablets," Current Terapeutic Research, vol. 47, No. 5, May 1990, pp. 869-878.
84 Kaiko R.F., "Clinical Protocol and Role of Controlled Release Morphine in the Surgical Patient," Anesthesiology and Pain Management 1991 pp. 193-212.
85 Lippold, B. C., Constant or Pulsed Delivery of Active Substance?, Pharmacie in uns Zeit, Jan. 13-31, 1990, No. 1.
86 M.H. Beers: "The Merck Index, 11th edition," 1989, Merck & Co. CP002606249.
87 Maccarrone C. et al.,"Single Dose Pharmacokinetics of Kapanol™ a New Oral Sustained-Release Morphine Formulation,"Clinical Drug Investigation 1994:7 (5) 262-274.
88 McTaggart, Celia M., et al., "The evaluation of formulation and processing conditions of a melt granulation process," International Journal of Pharmaceutics, vol. 19, pp. 139-148 (1984).
89 Merk Index, 13th edition, entry 4806: hydrocodone (2001).
90 MS Contin® Prescribing Information 2012.
91 MS Contin—Frequency of Daily Dosing (NDTI)—Jun. 1991-May 1992.
92 MS Contin-Frequency of Daily Dosing, Jan.-Nov. 1990.
93 MS Contin—Frequency of Daily Dosing, Jan.-Nov. 1990.
94 Office Action issued on Jul. 27, 2012, in connection with European Application No. 01 992 565.0/2123.
95 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 177 508.8-2123.
96 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 179 086.3-2123.
97 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 180 945.7.
98 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 180 984.6.
99 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 181 032.3.
100 Office Action issued on May 24, 2011, in connection with European Application No. 10 179 087.1-2123.
101 Opinion Expressed by the Board of Appeal in the Summons to Oral Proceedings in Case EP02026247 ( May 24, 2011).
102 Oxycontin® Prescribing Information 2010.
103 Patient consent forms, apparently for four study participants, 2003.
104 Physicians Desk Reference 1994, 48th Edition, pp. 1821-1824.
105 Physician's Desk Reference 57th ed. 2003 p. 1184-1185 (package insert information for ACTIQ).
106 Plummer JL, et al., "A comparison of Kapanol™ (a new sustained release morphine formulation) MST Continus™ and mophine solution in cancer patients: pharmcodynamic aspects," (Abstract 1000) International Association for the Study of Pain, 7th World Congress on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
107 Portenoy et al. "Fentanyl Buccal Tablet (FBT) for Relief of Breakthrough Pain in Opioid-Treated Patients with Chronic Low Back Pain", Current Medical Research and Opinion, vol. 23(7), pp. 223-233, 2007.
108 Portenoy et al. "Fentanyl Buccal Tablet (FBT) for Relief of Breakthrough Pain in Opioid-Treated Patients with Chronic Low Back Pain: A Randomized, Placebo- Controlled Study", ASRA 06, Final Abstract, Submitted Aug. 4, 2007.
109 R.K. Kaiko, "The Pre-and Postoperative Use of Controlled-Release Morphine (MS Contin Tablets): A Review of the Published Literature," Medical Department, The Pudue Frederick Company, Royal Society of Medical Services, International Congress, Symposium Services, No. 149, pp. 147-160 (1989).
110 R.K. Portenoy, et al., "A Randomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Pharmacolinetics and Pharmacodynamics of Kapanol® Capsules Given Every 24 hours and Every 12 hours with MS Contin® Tablets Given Every 12 Hours in the Management of Patients with Moderate to Severe Chronic Pain," Memorial Hospital IRB Protocol pp. 379-381, 1993.
111 Ratain M J et al., "Population Pharmacodynamic Study of Amonafide: A Cancer and Leukemia Group B Study," Journal of Clinical Oncology, Grune and Stratton, New York, NY, US, vol. 13, No. 3, Mar. 1995, pp. 741-747, XP008044974 ISSN: 0732-183X.
112 Robert F. Kaiko, et al., "Controlled-Release Morphine Bioavailability (MS Contin Tablets) in the Presence and Absence of Food," The Hospice Journal, vol. 6(4) 1990, pp. 17-30.
113 S. Bloomfield, et al., "Analgesic Efficacy and Potency of Two Oral Controlled-Release Morphine Preparations Clin. Pharmacol,"Ther., vol. 53, No. 4, pp. 469-478, 1993.
114 Santus G., and Baker. R.W., "Osmotic drug delivery: a review of the patent literature," J Controlled Release (1995) vol. 35 pp. 1-21.
115 Schaefer, T., et al., "Melt granulation in a laboratory scale high shear mixer," Drug Development and Industrial Pharmacy, vol. 16, No. 8, pp. 1249-1277 (1990).
116 Setiabidu R et al., "Dapsone N-Acetylation, Metoprolol, Alpha-Hydroxylation, and S-Mephenytoin 4-Hydroxylation Polymorphisms in an Indonesian Population: A Cocktail and Extended Phenotyping Assessment Trail," Clinical Pharmacology & Therapeutics, Mosby-Year Book, St Louis, MO, US, vol. 56, No. 2, Aug. 1994, pp. 142-153, XP008044975 ISSN: 0009-9236.
117 Shah et al., J. Cont. Rel. (1989) 9:169-175.
118 Siepmann et al., "A New Model Describing the Swelling and Drug Release Kinetics from Hydroxypropyl Methylcellulose Tablets", Journ. of Pharmaceutical Sciences, vol. 88, No. 1, pp. 65-72, Jan. 1999.
119 Summons to Attend Oral Proceedings issued in connection with European Patent Application No. 05019453.9 on Jul. 23, 2010.
120 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 01992565.0.
121 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10177508.8.
122 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10179086.3.
123 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10179087.1.
124 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10180984.6.
125 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10181032.3.
126 Sung et al., "Effect of Formulation Variables on Drug and Polymer Release from HPMC-Based Matrix Tablets", International Journ. of Pharmaceutics vol. 142, pp. 53-60, 1996.
127 Sustained Release Medications, Noyes Data Corp., pp. 3,4, 10-15, 96-99, 335-337 (1980).
128 T. Hunt and R. Kaiko, "Comparison of the Pharmacokinetic Profiles of Two Oral Controlled-Release Morphine Formulation in Healthy Young Adults," Clin. Thera., vol. 13, No. 4, pp. 482-488, 1991.
129 The Advisory Action issued in connection with U.S. Appl. No. 12/982,386 on Dec. 19, 2014.
130 The Advisory Action issued in connection with U.S. Appl. No. 12/982,386 on Oct. 9, 2014.
131 The Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 12/982,386 on Apr. 18, 2013.
132 The Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 13/833,263 on May 12, 2014.
133 The Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 13/833,263 on Nov. 3, 2014.
134 The Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 14/094,968 on May 9, 2014.
135 The Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 14/094,968 on Nov. 5, 2014.
136 The Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 14/483,395 on Oct. 3, 2014.
137 The claims pending in U.S. Appl. No. 12/982,386 on Nov. 17, 2014.
138 The claims pending in U.S. Appl. No. 13/833,263 on Nov. 17, 2014.
139 The claims pending in U.S. Appl. No. 14/094,968 on Nov. 17, 2014.
140 The claims pending in U.S. Appl. No. 14/483,395 on Nov. 17, 2014.
141 The Decision to refuse a European Patent application issued in connection with European patent application No. 01992565.0-1464 on Jun. 27, 2014.
142 The Decision to refuse a European Patent application issued in connection with European patent application No. 10 180 984.6-1464 on Jul. 9, 2014.
143 The Declaration of Benjamin Oshlack filed in U.S. Appl. No. 13/833,263 on Dec. 24, 2014.
144 The Merck Index, eleventh edition, pp. 757 and 1100 (1989).
145 The Office Action issued in connection with Chinese Patent Application No. CN 201210130057.4 on Oct. 11, 2014.
146 The Office Action issued in connection with Japanese patent application No. 2013-168584 on Sep. 16, 2014.
147 The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Apr. 10, 2012.
148 The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Apr. 30, 2013.
149 The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Aug. 13, 2014.
150 The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Dec. 19, 2013.
151 The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Dec. 27, 2012.
152 The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Feb. 26, 2014.
153 The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Nov. 5, 2012.
154 The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Oct. 9, 2014.
155 The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Sep. 4, 2013.
156 The Office Action issued in connection with U.S. Appl. No. 13/833,263 on Feb. 6, 2014.
157 The Office Action issued in connection with U.S. Appl. No. 13/833,263 on Jun. 23, 2014.
158 The Office Action issued in connection with U.S. Appl. No. 13/833,263 on Oct. 7, 2014.
159 The Office Action issued in connection with U.S. Appl. No. 14/094,968 on Feb. 6, 2014.
160 The Office Action issued in connection with U.S. Appl. No. 14/094,968 on Jun. 24, 2014.
161 The Office Action issued in connection with U.S. Appl. No. 14/094,968 on Oct. 3, 2014.
162 The Office Action issued in connection with U.S. Appl. No. 14/483,395 on Oct. 9, 2014.
163 The Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Apr. 10, 2012.
164 The Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Apr. 30, 2013.
165 The Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Aug. 13, 2014.
166 The Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Feb. 26, 2014.
167 The Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Nov. 5, 2012.
168 The Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Sep. 4, 2014.
169 Thomsen, L. Juul, "Prolonged Release Matrix Pellets prepared by Melt Pelletization II. Hydrophobic Substances as Meltable Binders," vol. 20, No. 77, pp. 1179-1197 (1994).
170 Thomsen, L. Juul, "Prolonged Release Matrix Pellets Prepared by Melt Pelletization. Part IV: Drug Particles Size, and Binder Composition," Pharmaceutical Technology Europa, pp. 19-24 (Oct. 1994).
171 Thomsen, L. Juul, "Utilizing melt pelletization technique for the preparation of prolonged release products," Pelletization, (material elaborated by assistant prof. Lars Jull Thomsen, Department of Pharmaceutics, Royal Danish School of Pharmacy of the DIE course "Pelletization Technology," Nov. 1992, 106 pages plus 3 appendices.
172 Thomsen, L. Juul, et al., "Prolonged Release Matrix Pellets Prepared by Melt Pelletization I. Process Variables," Drug Development and Industrial Pharmacy, vol. 19, No. 15, pp. 1867-1887 (1993).
173 Toner G, Cramond T, Bishop, et al., "Randomized double blind, phase III crossover study of a new sustained-release oral mophine fornulation, Kapanol™ capsules," (Abstract 1001) International Association for the Study on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
174 Trandemate ER® Prescribing Information 2005.
178 West R. J., et al., "Single dose pharmacokinetics of a new oral sustained release morphine formulation, Kapanol™ capsules," (Abstract 997) International Association for the Study of Pain, 7th World Congress on Pain. Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
179 Wiktionary, "dispersed," p. 1, http://en.wiktionary.org/wiki/disperse retrived on Apr. 30, 2006.
180 Yokokawa N., et al., "Relationship between plasma concentration of morphine and analgesic effectiveness," Postgrad Med J. (1991) 67 (Suppl. 2) pp. S50-S54.
181 Zimm et al., Pharmaceutical Development and Technology, 1(1), 37-42 (1996) "Drug Release from a Multiparticulate Pallet System."
182 Zohydro ER Hydrocodone Bitartrate Extended-Release (HC-ER) Dec. 7, 2012.
183 Zohydro ER Package Insert revised Oct. 2013.
US9278074 * 30 Mar 2015 8 Mar 2016 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20150216810 * 30 Mar 2015 6 Ago 2015 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20150265537 * 2 Jun 2015 24 Sep 2015 Purdue Pharma L.P. Controlled release hydrocodone formulations
Clasificación de EE.UU. 424/541
Clasificación internacional C07D489/02, A61K9/22, A61K9/48, A61K9/26, A61K31/485, A61K9/24, A61K9/52, A61K9/00, A61K31/194, A61P25/04, A61K9/20, A61K9/54
Clasificación cooperativa A61K31/485, A61K9/2077, A61K9/2018, A61K9/2031, A61K9/205, A61K9/2009, A61K9/2013, A61K9/0053, A61K9/2086, A61K9/2072, A61K9/2054, A61K9/141, A61K31/46, A61K9/0004, A61K9/2027, A61K31/194